Promacta

Low Platelet Count, chronic immune thrombocytopenia, Interferon Treatment + 7 more
Treatment
20 Active Studies for Promacta

What is Promacta

EltrombopagThe Generic name of this drug
Treatment SummaryEltrombopag is a medication used to treat low platelet counts in adults with chronic immune thrombocytopenia (ITP), when other treatments such as surgery have not been effective. It is also approved for use in people with hepatitis C to help them start and maintain interferon-based therapy. Eltrombopag can help reduce unusual bruising and bleeding caused by having too few platelets in the blood.
Promactais the brand name
image of different drug pills on a surface
Promacta Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Promacta
Eltrombopag
2008
13

Effectiveness

How Promacta works in the bodyEltrombopag is a drug taken orally that helps to increase platelet counts. It does this by interacting with and stimulating a specific protein in the body, called the TPO-receptor. This stimulation causes platelet production to increase, and potentially other lineages as well. It does not activate the AKT pathway, which means that it does not work in the same way as other drugs used to treat aplastic anemia.

When to interrupt dosage

The proposed dosage of Promacta is dependent upon the diagnosed disorder, including Aplastic Anemia, Chronic Hepatitis C and Low Platelet Count. The quantity of dosage can be deduced from the table below, contingent upon the delivery system (e.g. Tablet - Oral or Oral).
Condition
Dosage
Administration
Immunosuppressive Treatment
100.0 mg, , 75.0 mg, 50.0 mg, 25.0 mg, 12.5 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Powder, for suspension, Powder, for suspension - Oral
Aplastic Anemia
100.0 mg, , 75.0 mg, 50.0 mg, 25.0 mg, 12.5 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Powder, for suspension, Powder, for suspension - Oral
Chronic Hepatitis C
100.0 mg, , 75.0 mg, 50.0 mg, 25.0 mg, 12.5 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Powder, for suspension, Powder, for suspension - Oral
Low Platelet Count
100.0 mg, , 75.0 mg, 50.0 mg, 25.0 mg, 12.5 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Powder, for suspension, Powder, for suspension - Oral
chronic immune thrombocytopenia
100.0 mg, , 75.0 mg, 50.0 mg, 25.0 mg, 12.5 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Powder, for suspension, Powder, for suspension - Oral
Treatment Naive
100.0 mg, , 75.0 mg, 50.0 mg, 25.0 mg, 12.5 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Powder, for suspension, Powder, for suspension - Oral
Therapeutic procedure
100.0 mg, , 75.0 mg, 50.0 mg, 25.0 mg, 12.5 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Powder, for suspension, Powder, for suspension - Oral
Interferon Treatment
100.0 mg, , 75.0 mg, 50.0 mg, 25.0 mg, 12.5 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Powder, for suspension, Powder, for suspension - Oral
Therapeutic immunosuppression
100.0 mg, , 75.0 mg, 50.0 mg, 25.0 mg, 12.5 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Powder, for suspension, Powder, for suspension - Oral
inadequate response to other therapeutic measures
100.0 mg, , 75.0 mg, 50.0 mg, 25.0 mg, 12.5 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet - Oral, Tablet, Powder, for suspension, Powder, for suspension - Oral

Warnings

There are 20 known major drug interactions with Promacta.
Common Promacta Drug Interactions
Drug Name
Risk Level
Description
Amiodarone
Major
The metabolism of Amiodarone can be decreased when combined with Eltrombopag.
Axitinib
Major
The metabolism of Axitinib can be decreased when combined with Eltrombopag.
Belinostat
Major
The metabolism of Belinostat can be decreased when combined with Eltrombopag.
Binimetinib
Major
The metabolism of Binimetinib can be decreased when combined with Eltrombopag.
Brigatinib
Major
The metabolism of Brigatinib can be decreased when combined with Eltrombopag.
Promacta Toxicity & Overdose RiskTaking eltrombopag can cause liver damage, especially if combined with interferon and ribavirin when treating chronic hepatitis C. This can increase the risk of liver failure.
image of a doctor in a lab doing drug, clinical research

Promacta Novel Uses: Which Conditions Have a Clinical Trial Featuring Promacta?

59 active clinical trials are currently being conducted to assess the efficacy of Promacta in relieving Aplastic Anemia, Low Platelet Count and Thrombocytopenia.
Condition
Clinical Trials
Trial Phases
Chronic Hepatitis C
0 Actively Recruiting
inadequate response to other therapeutic measures
0 Actively Recruiting
Immunosuppressive Treatment
0 Actively Recruiting
Aplastic Anemia
17 Actively Recruiting
Phase 2, Phase 1, Not Applicable, Phase 3
chronic immune thrombocytopenia
0 Actively Recruiting
Treatment Naive
0 Actively Recruiting
Low Platelet Count
7 Actively Recruiting
Phase 2, Not Applicable, Early Phase 1
Interferon Treatment
0 Actively Recruiting
Therapeutic procedure
0 Actively Recruiting
Therapeutic immunosuppression
0 Actively Recruiting

Promacta Reviews: What are patients saying about Promacta?

5Patient Review
8/18/2011
Promacta for Severe Low Platelet Count in Unresponsive Chronic ITP
Promacta has been an absolute lifesaver for me. If you're struggling with chronic ITP, it's definitely worth considering this treatment option. Just be sure to talk to your hematologist first and be aware of the potential side effects.
5Patient Review
9/6/2009
Promacta for Severe Low Platelet Count in Unresponsive Chronic ITP
This treatment has been crucial in maintaining my platelet count above 200. It's easy to take and I don't have to go for a platelet transfusion every week like I used to.
4.7Patient Review
9/22/2010
Promacta for Severe Low Platelet Count in Unresponsive Chronic ITP
I have been taking 50mg Promacta for about 3 weeks now and platelets have risen from 34 to 140. So far, the only side effect I think is mild indigestion. This medication has been working well for me so far and I'm hopeful that my platelet count will continue to rise.
4.7Patient Review
7/15/2011
Promacta for Severe Low Platelet Count in Unresponsive Chronic ITP
I've been on Promacta for about two years now and it has really helped to regulate my platelet levels. I was getting monthly blood tests anyway, but they've all come back looking good since I started this medication.
4.3Patient Review
1/29/2010
Promacta for Severe Low Platelet Count in Unresponsive Chronic ITP
My platelet count has stayed at a steady 90,000 since I began this treatment; however, I have developed watery eyes and my hair has lost its curl. Additionally, my blood pressure has risen to an unhealthy 170/103. As a result, I now have to take more medication for high blood pressure. My insurance company isn't thrilled about the price tag of this drug, but it seems to be working well for me so far.
4Patient Review
12/14/2010
Promacta for Severe Low Platelet Count in Unresponsive Chronic ITP
I have also lost the curl in my hair. My eyes water and my blood pressure is a little high, but those aren't the real problems I have. The cost is what really concerns me; $160/month for just 75mg?
4Patient Review
4/25/2011
Promacta for Severe Low Platelet Count in Unresponsive Chronic ITP
I've been taking this for a month and it's working well, but I recently got hit with a severe cold that has left me congested for the past two weeks. The doctor doesn't think it's related to the medication, but it is clearly disclosed as a possible side effect.
4Patient Review
1/26/2021
Promacta for Severe Low Platelet Count in Unresponsive Chronic ITP
I was diagnosed with ITP and my platelet count was below 10. My doctor recommended the generic Eltrombopag from BonHoa Pharmacy. I have been taking 25mg daily for 3 months and my platelet count is now in the 70 to 90 range. I have no side effects and my doctor expects me to be on the medication long-term.
4Patient Review
10/21/2011
Promacta for Severe Low Platelet Count in Unresponsive Chronic ITP
My platelet count increased from 20000 to 156000 in just 15 months.
3.7Patient Review
3/16/2011
Promacta for Severe Low Platelet Count in Unresponsive Chronic ITP
My son has been on this medication for two years now with mixed results. His platelet count will range from 1,000 to 425,000 while he's on the drug; however, whenever he gets even a slight cold or illness, his count severely drops and the medication doesn't seem effective at all.
3.3Patient Review
4/15/2013
Promacta for Low Platelet Count in Chronic Hepatitis C Infection
Recently finished hep C treatment and was put on Promacta. It's only been a week, but I've already noticed an improvement in my condition.
2.7Patient Review
9/16/2009
Promacta for Severe Low Platelet Count in Unresponsive Chronic ITP
So far, the only side effect I've experienced is back pain. I'm hoping that certain foods or vitamins can help to increase the effectiveness of this medication, but I haven't seen any improvement yet.
2Patient Review
9/9/2009
Promacta for Severe Low Platelet Count in Unresponsive Chronic ITP
I experienced significant side effects with this treatment, including bleeding in the eye, chest pain, numbness in legs and hands, severe headache, nausea, and drainage of the eye.
2Patient Review
3/13/2013
Promacta for Severe Low Platelet Count in Unresponsive Chronic ITP
I was prescribed Promacta and Rituxin, but unfortunately ended up in the ER with a blood clot in my liver. I can't say for sure that either of these drugs caused it, but I suspect they played a role. Either way, patients should be closely monitored by a hematologist and any side effects should be investigated immediately!
1.7Patient Review
8/5/2011
Promacta for Severe Low Platelet Count in Unresponsive Chronic ITP
I started with 50 MG, but saw no difference in my platelet count. In fact, the next month they dropped. I increased my dosage to 75 MG, but still saw no significant change. For how much this treatment costs, I expected miracles!
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about promacta

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of PROMACTA?

"The most common side effects of the medication are nausea, diarrhea, and an upper respiratory tract infection, which may include a runny nose, stuffy nose, and sneezing. Other common side effects include vomiting and a urinary tract infection."

Answered by AI

What type of medication is PROMACTA?

"This medication is used to treat low platelet levels in people who have a certain blood disorder called chronic immune (idiopathic) thrombocytopenia purpura (ITP). It may also be used to treat people with a certain blood disorder (aplastic anemia)."

Answered by AI

What is PROMACTA used for?

"PROMACTA is a prescription medicine used to increase blood platelet counts in adults and children who have persistent or chronic immune thrombocytopenia (ITP). PROMACTA may be used when other medicines to treat ITP or surgery to remove the spleen have not worked well enough."

Answered by AI

Clinical Trials for Promacta

Image of Weill Cornell Medical College in New York, United States.

Luspatercept for Clonal Cytopenia

18+
All Sexes
New York, NY
The purpose of this clinical trial is to test how well the drug luspatercept works in improving low blood cell counts in people with clonal cytopenias of uncertain significance (CCUS). The main questions the study seeks to answer include: * How many patients experience improvements in their low blood counts (red cells, platelets, or white cells) within 24 weeks, based on specific criteria for blood conditions like myelodysplastic syndromes (MDS)? * How long these improvements last before the condition worsens or changes. * The percentage of participants showing improvements at 12, 24, and 48 weeks. * How long it takes for the condition to progress to more severe diseases like myeloid disorders. * How long red blood cell responses last and how quickly these responses are seen. * The average change in hemoglobin levels over 24 weeks. * How many patients need blood transfusions during the study and how soon transfusions are required. * Changes in participants' well-being and energy levels based on a standardized questionnaire. * Monitoring for any side effects, including progression to MDS or leukemia, heart-related issues, or sudden increases in hemoglobin. Participants will: * Receive luspatercept as an injection every three weeks. * Visit the clinic every three weeks for treatment and monitoring.
Phase 2
Recruiting
Weill Cornell Medical CollegePinkal Desai, MDBristol-Myers Squibb
Have you considered Promacta clinical trials? We made a collection of clinical trials featuring Promacta, we think they might fit your search criteria.Go to Trials
Image of National Institutes of Health Clinical Center in Bethesda, United States.

Ruxolitinib for Bone Marrow Failure

18 - 99
All Sexes
Bethesda, MD
Background: Immune bone marrow failure is a condition that occurs when a person s immune system attacks the cells of the bone marrow. This can lead to diseases including different types of anemias and blood cancers. Some of these diseases can be deadly. Better treatments are needed. Objective: To test a drug (ruxolitinib) in people with different types of immune bone marrow failure. Eligibility: Adults aged 18 and older with an immune bone marrow failure. Design: Participants will be screened. They will have a physical exam. They will give samples of blood and saliva. They will have a bone marrow biopsy: A large needle will be inserted into a small cut to remove a sample of the soft tissue inside the bone. Some participants may have a skin biopsy: A small piece of skin will be removed. Some may have a computed tomography (CT) scan: They will lie on a table that slides into a donut-shaped machine that uses X-rays to make pictures of the inside of the body. Ruxolitinib is a tablet taken by mouth. Participants will take the drug twice a day for up to 6 months. Participants will have blood tests every week while they are taking the drug. These tests can be done by the participant s own physician and the results sent to the researchers. Participants will have clinic visits after taking the drug for 3 months and 6 months and then after 1, 2, and 3 years. The blood tests and bone marrow biopsy will be repeated. Participants who improve while taking the drugs may go on to an extension phase of the study.
Phase 1 & 2
Recruiting
National Institutes of Health Clinical CenterEmma M Groarke, M.D.
Have you considered Promacta clinical trials? We made a collection of clinical trials featuring Promacta, we think they might fit your search criteria.Go to Trials
Image of National Institutes of Health Clinical Center in Bethesda, United States.

Cyclosporine + Eltrombopag for Aplastic Anemia

3 - 99
All Sexes
Bethesda, MD
Background: Severe aplastic anemia (SAA) is a rare and serious blood disorder. It causes the immune system to turn against bone marrow cells. Standard treatment for SSA is a combination of 3 drugs (Cyclosporine \[CsA\], Eltrombopag \[EPAG\], and horse anti-thymocyte globulin \[h-ATG\]). Researchers want to see if starting people at a lower dose of CsA with EPAG before giving them h-ATG is helpful. Objective: To learn if early initiation of oral therapy with CsA and EPAG is safe and effective in people who have SAA and have not been treated with a course of immunosuppressive therapy and EPAG. Eligibility: People ages 3 and older with SAA Design: Participants will be screened with: medical history physical exam electrocardiogram blood tests family history bone marrow biopsy current medicines. Participants may be screened remotely via telephone conference. Participants will take a lower oral dose of CsA and EPAG. They will take CsA twice a day for 6 months. They will take EPAG for 6 months. Those who cannot visit the NIH Clinical Center within 72 hours will start taking the drugs at home. They will have weekly telephone calls with NIH staff until they visit the Clinical Center. Participants may get h-ATG at the Clinical Center for 4 days. For this, they will have a central line placed. It is a plastic tube inserted into a neck, chest, or arm vein. Participants will repeat most screening tests throughout the study. Participants will have follow-up visits at the Clinical Center at 3 months, 6 months, and annually for 5 years after the start of the study....
Phase 2
Recruiting
National Institutes of Health Clinical CenterBhavisha A Patel, M.D.
Have you considered Promacta clinical trials? We made a collection of clinical trials featuring Promacta, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security